IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.361
AS - Asia 1.333
EU - Europa 1.301
SA - Sud America 104
Continente sconosciuto - Info sul continente non disponibili 8
AF - Africa 7
OC - Oceania 4
Totale 16.118
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.344
SG - Singapore 660
IE - Irlanda 297
CN - Cina 279
HK - Hong Kong 242
IT - Italia 208
DE - Germania 180
RU - Federazione Russa 162
UA - Ucraina 115
SE - Svezia 89
BR - Brasile 88
GB - Regno Unito 70
FR - Francia 64
KR - Corea 44
FI - Finlandia 34
IN - India 21
ID - Indonesia 17
NL - Olanda 14
PL - Polonia 14
AT - Austria 13
KG - Kirghizistan 12
CA - Canada 11
ES - Italia 9
BE - Belgio 7
MY - Malesia 7
TR - Turchia 7
UZ - Uzbekistan 7
EU - Europa 6
JP - Giappone 6
CL - Cile 5
CZ - Repubblica Ceca 5
AU - Australia 4
BD - Bangladesh 4
CH - Svizzera 4
GR - Grecia 4
IL - Israele 4
PH - Filippine 4
RO - Romania 4
VE - Venezuela 4
CO - Colombia 3
PK - Pakistan 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
DK - Danimarca 2
EG - Egitto 2
JO - Giordania 2
MX - Messico 2
NP - Nepal 2
SI - Slovenia 2
VC - Saint Vincent e Grenadine 2
VN - Vietnam 2
ZA - Sudafrica 2
BN - Brunei Darussalam 1
CG - Congo 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 16.118
Salva come PNG Salva come JPEG
Città #
Wilmington 3.382
Houston 3.220
Woodbridge 2.182
Fairfield 872
Chandler 510
Ashburn 500
Singapore 440
Seattle 391
Cambridge 307
Ann Arbor 301
Dublin 280
Hong Kong 242
Medford 210
Beijing 120
Santa Clara 110
Dearborn 102
Lawrence 101
Jacksonville 80
San Diego 63
The Dalles 52
New York 48
Rome 48
Council Bluffs 46
Moscow 46
Munich 39
Zhengzhou 30
London 24
Redwood City 24
Nuremberg 20
Shanghai 20
Menlo Park 18
Jakarta 17
Seoul 17
Boardman 14
Falls Church 14
Kraków 14
Esslingen am Neckar 13
Milan 13
Pune 13
Norwalk 12
Guangzhou 11
Helsinki 11
Mountain View 10
São Paulo 10
Los Angeles 9
Saint Petersburg 9
Del Norte 8
Hefei 8
Perugia 8
Brussels 7
Mülheim 7
Ottawa 7
Detroit 6
Nanchang 6
Nanjing 6
San Mateo 6
Brno 5
Frosinone 5
Palo Alto 5
Putrajaya 5
Vienna 5
Belo Horizonte 4
Chengdu 4
Engelhard 4
Espoo 4
Kilburn 4
Manila 4
Renton 4
Valencia 4
Washington 4
Bochum 3
Casarile 3
Coushatta 3
Dhaka 3
Hebei 3
Hyderabad 3
Islington 3
Jinan 3
Lausanne 3
Madrid 3
Padova 3
Rapallo 3
Salt Lake City 3
San Giorgio di Nogaro 3
Shenzhen 3
Toronto 3
Wandsworth 3
Wuhan 3
Amman 2
Ankara 2
Augusta 2
Berlin 2
Bologna 2
Cairo 2
Campo Grande 2
Caratinga 2
Chions 2
Clearwater 2
Croydon 2
Dong Ket 2
Totale 14.223
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 456
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 449
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 400
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 397
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 393
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 392
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 392
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 392
Tildrakizumab for treating psoriasis 392
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 376
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 375
Brodalumab for the treatment of psoriasis 373
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 372
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 370
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 366
Tofacitinib for the treatment of psoriasis 356
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 346
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 338
A safety evaluation of guselkumab for the treatment of psoriasis 312
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 305
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 304
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 284
Photo-recall cutaneous reaction to gemcitabine 280
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 277
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 275
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 271
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 256
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 250
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 248
Pharmacotherapeutic management of psoriasis in adolescents and children 244
Skin immunity and its dysregulation in psoriasis 228
Successful treatment of psoriatic crumbly nails with ustekinumab 218
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 214
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 206
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 196
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 190
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 174
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 172
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 168
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 165
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 153
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 148
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 146
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 139
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 128
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 122
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 116
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 110
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 108
Efalizumab 106
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 102
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 92
Genetic markers predictive of clinical response to biological drugs in psoriasis. 90
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 87
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 80
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 80
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 79
Italian guidelines in diagnosis and treatment of alopecia areata 78
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 78
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 77
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 77
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 76
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 76
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 75
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 72
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 72
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 69
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 66
Long-term efficacy of adalimumab in generalized pustular psoriasis 59
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 58
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 58
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 57
Clinical severity instruments 55
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 55
Linear psoriasis following the typical distribution of the sciatic nerve 54
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 54
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 53
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 52
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 51
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 51
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 50
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 49
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 49
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 47
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 47
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 45
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 45
Genetic variations in IL6 and IL12B as protective markers for psoriasis 45
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 44
Pruritus characteristics in a large Italian cohort of psoriatic patients 44
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 43
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 42
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 42
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 42
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 41
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 39
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 38
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 35
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 35
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes 34
Totale 16.387
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.964
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.182 0 0 0 0 0 0 0 0 0 546 336 300
2020/20213.515 331 347 325 385 418 506 401 344 118 166 124 50
2021/20221.134 65 101 107 35 29 52 139 42 84 87 84 309
2022/20231.216 142 125 104 117 78 299 91 61 102 21 45 31
2023/2024524 41 14 22 13 65 121 68 64 4 8 27 77
2024/20251.852 121 453 268 238 33 231 152 99 221 36 0 0
Totale 16.771